U.S., Jan. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07331389) titled 'A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin' on Nov. 18, 2025.
Brief Summary: The purpose of this study is to characterize the drug-drug intereaction of HDM1002 and metformin, empagliflozin, midazolam, valsartan, and warfarin in overweight/obese adult subjects. The safety and tolerability of HDM1002 with metformin, empagliflozin, midazolam, valsartan, and warfarin when given separately or together will also be evaluated
Study Start Date: Sept. 24, 2025
Study Type: INTERVENTIONAL
Condition:
Overweight Subject
Healthy Subjects
Intervention:
DRUG: Metformin
Administer...